Article
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2024
Innocenti Federico, Mu Wancen, Qu Xueping, Ou Fang-Shu, Kabbarah Omar, Blanke Charles David, Venook Alan P, Lenz Heinz-Josef, Rashid Naim U
Abstract excerpt
PURPOSE: CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab with chemotherapy. We aimed to discover novel mutated genes associated with prognosis and differential response to therapy with the biologics. METHODS: Primary tumor DNA from 548 patients was sequenced using FoundationOne. The effect of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
